OncoZenge reports 92% subscription rate in rights issue
OncoZenge AB's preliminary rights issue results indicate that approximately 92% of shares were subscribed for, with expected gross proceeds of SEK 30.7 million before costs. The subscription guarantee commitment from Vator Securities Ab is not expected to be utilized.